Ocugen Inc. stock falls Wednesday, underperforms market
Shares of Ocugen Inc. OCGN shed 5.16% to $0.83 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.16% to 5,918.25 and the Dow Jones Industrial Average DJIA rising 0.
Dow Jones Futures Fall; What To Do After Stock Market Sell-Off; Nvidia, Palantir Tumble
Futures fell as Treasury yields kept rising after the stock market sold off Tuesday. Here's what to do now. These freshly redesigned mid-size SUVs both have an off-road focus. Here's how they stack up in terms of passenger and cargo space,
ArMaDa clinical trial is set to assess the safety and efficacy of unilateral subretinal administration of OCU410 in patients ...
Ocugen Inc (OCGN) stock saw a modest uptick, ending the day at $0.9 which represents a slight increase of $0.09 or 11.11% from the prior close of $0.81. The stock opened at $0.87 and touched a low of ...
Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies ...
Maxim Group analyst Michael Okunewitch maintained a Buy rating on Lineage Therap (LCTX – Research Report) yesterday. The company’s shares ...
Maxim Group has recently initiated Ocugen Inc (OCGN) stock to Buy rating, as announced on October 15, 2024, according to Finviz. Earlier, on March 1, 2023, Chardan Capital Markets had raised the stock ...
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410 ...
Geode Capital Management LLC grew its stake in shares of Ocugen, Inc. (NASDAQ:OCGN – Free Report) by 6.3% in the third quarter, according to its most recent disclosure with the SEC. The fund owned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback